[go: up one dir, main page]

ZA200703306B - Use of epothilones in the treatment of bone metastases and bone tumors or cancers - Google Patents

Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Info

Publication number
ZA200703306B
ZA200703306B ZA200703306A ZA200703306A ZA200703306B ZA 200703306 B ZA200703306 B ZA 200703306B ZA 200703306 A ZA200703306 A ZA 200703306A ZA 200703306 A ZA200703306 A ZA 200703306A ZA 200703306 B ZA200703306 B ZA 200703306B
Authority
ZA
South Africa
Prior art keywords
bone
epothilones
cancers
treatment
tumors
Prior art date
Application number
ZA200703306A
Other languages
English (en)
Inventor
Jens Hoffmann
Hubertus Pietsch
Ulrich Klar
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200703306(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200703306B publication Critical patent/ZA200703306B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA200703306A 2004-09-24 2007-04-23 Use of epothilones in the treatment of bone metastases and bone tumors or cancers ZA200703306B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090377A EP1640004A1 (en) 2004-09-24 2004-09-24 Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Publications (1)

Publication Number Publication Date
ZA200703306B true ZA200703306B (en) 2010-06-30

Family

ID=34928830

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703306A ZA200703306B (en) 2004-09-24 2007-04-23 Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Country Status (21)

Country Link
EP (2) EP1640004A1 (xx)
JP (1) JP2008514569A (xx)
KR (1) KR20070054214A (xx)
CN (1) CN101065126A (xx)
AR (1) AR051035A1 (xx)
AU (1) AU2005287477A1 (xx)
BR (1) BRPI0516080A (xx)
CA (1) CA2580215A1 (xx)
CR (1) CR9064A (xx)
EC (1) ECSP077390A (xx)
GT (1) GT200500267A (xx)
IL (1) IL181785A0 (xx)
MX (1) MX2007003503A (xx)
NO (1) NO20072099L (xx)
PA (1) PA8646201A1 (xx)
PE (1) PE20060695A1 (xx)
RU (1) RU2007115162A (xx)
TW (1) TW200626150A (xx)
UY (1) UY29136A1 (xx)
WO (1) WO2006032537A2 (xx)
ZA (1) ZA200703306B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930004A1 (en) * 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Use of epothilones in the treatment of osteoporosis and related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
BR9916833A (pt) * 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
AR023792A1 (es) * 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
EP1229934B1 (en) * 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004508810A (ja) * 2000-04-28 2004-03-25 コーサン　バイオサイエンシーズ，　インコーポレイテッド ポリケチドの生成
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002338336A1 (en) * 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
WO2003092683A1 (en) * 2002-05-01 2003-11-13 Novartis Ag Epothilone derivative for the treatment of hepatoma and other cancer diseases
EP1581218A1 (en) * 2002-12-05 2005-10-05 Schering AG Epothilone analogs for site specific delivery in the treatment of proliferative diseases
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
CA2530311A1 (en) * 2003-06-27 2005-01-06 Novartis Ag Cancer treatment with epothilones
JP2007504259A (ja) * 2003-09-02 2007-03-01 ノバルティス アクチエンゲゼルシャフト エポチロンでの癌処置

Also Published As

Publication number Publication date
PE20060695A1 (es) 2006-08-03
UY29136A1 (es) 2006-04-28
KR20070054214A (ko) 2007-05-28
IL181785A0 (en) 2007-07-04
WO2006032537A3 (en) 2006-05-04
PA8646201A1 (es) 2006-11-09
AR051035A1 (es) 2006-12-13
CR9064A (es) 2007-10-01
CA2580215A1 (en) 2006-03-30
CN101065126A (zh) 2007-10-31
MX2007003503A (es) 2007-08-17
JP2008514569A (ja) 2008-05-08
GT200500267A (es) 2006-06-06
TW200626150A (en) 2006-08-01
RU2007115162A (ru) 2008-11-20
ECSP077390A (es) 2007-05-30
WO2006032537A2 (en) 2006-03-30
BRPI0516080A (pt) 2008-08-19
NO20072099L (no) 2007-04-23
EP1640004A1 (en) 2006-03-29
EP1809281A2 (en) 2007-07-25
AU2005287477A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
PL2100618T3 (pl) Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
PL1599467T3 (pl) Nowe pochodne cyjanopirydyny użyteczne w leczeniu raka i innych zaburzeń
PL1730303T3 (pl) Mutacje genu PIK3CA w nowotworach ludzkich
GB0504988D0 (en) Device and method for the treatment of diseased tissue such as tumors
IL188031A0 (en) Use of thiazole derivatives and analogues in the treatment of cancer
IL181608A0 (en) Cancer combination therapy comprising azd2171 and imatinib
ZA200703699B (en) Nitrobenzindoles and their use in cancer therapy
IL180810A0 (en) Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
IL173576A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
AU2003212634A8 (en) Compounds useful in the treatment of cancer
IL180138A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200709542B (en) Combination therapy in the treatment of cancer
SI1803456T1 (sl) Farmacevtski sestavki, ki obsegajo L-733060, za uporabo pri zdravljenju rakavih tumorjev
GB0326578D0 (en) Cancer diagnosis and therapy
ZA200800243B (en) Use of thiazole derivatives and analogues in the treatment of cancer
ZA200703306B (en) Use of epothilones in the treatment of bone metastases and bone tumors or cancers
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
ZA200604365B (en) Compositions and methods for the diagnosis and treatment of tumor
IL175774A0 (en) Use of siramesine in the treatment of cancer
GB0427637D0 (en) Topical formulations for use in the treatment or prevention of skin cancers
AU2003247094A8 (en) Enhancing the effect of radioimmunotherapy in the treatment of tumors